C. Silber

发表

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety

C. Tamminga, G. Granneman, K. Kashkin, 1997, International clinical psychopharmacology.

569 Reduction of hospital days in sertindole treated patients: One year findings

L. Ereshefsky, A. Nabulsi, R. Mack, 1997, Schizophrenia Research.

571 The action of sertindole on negative symptoms in schizophrenia

A. Lahti, R. Mack, C. Silber, 1997, Schizophrenia Research.

570 Population pharmacokinetics of sertindole during long-term treatment of patients with schizophrenia

P. Wozniak, R. Mack, T. Tran-Johnson, 1997, Schizophrenia Research.

574 A multi-center, one year, haloperidol controlled trial assessing the long term safety, efficacy and quality of life of sertindole in stable schizophrenic patients

A. Swann, R. Mack, K. Holgate, 1997, Schizophrenia Research.

Effect of Zuranolone vs Placebo in Postpartum Depression

H. Gunduz-Bruce, Sigui Li, B. Werneburg, 2021, JAMA psychiatry.

Migraine prophylaxis with divalproex.

S. Silberstein, J. Saper, A. Rapoport, 1995, Archives of neurology.

Trial of SAGE-217 in Patients with Major Depressive Disorder.

D. Rubinow, H. Gunduz-Bruce, C. Zorumski, 2019, The New England journal of medicine.

Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study

Sigui Li, S. Kanes, J. Doherty, 2020, Journal of the Neurological Sciences.

Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.

M. Kosinski, H. Gunduz-Bruce, B. Werneburg, 2022, Journal of affective disorders.

A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults

H. Gunduz-Bruce, G. Zammit, S. Kanes, 2021, Human psychopharmacology.

P.2.042 The long term cardiovascular safety of sertindole

R. Mack, C. Silber, R. Driscoll, 1997, European Neuropsychopharmacology.